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Abstract: Metastasis is characterized by the ability of cancer cells to
invade into adjacent tissue, intravasate into blood or lymphatic
vessels, and extravasate into a distant tissue. Metastatic disease is
primarily responsible for the low 5-year survival rate of non-small
cell lung cancer (NSCLC), and therefore, an understanding of the
molecular mechanisms that regulate NSCLC metastasis is clearly
warranted. The serine/threonine kinase and tumor suppressor LKB1
is mutated in 30% of NSCLC tumors, and recent evidence points to
a prominent role in NSCLC metastasis. This review summarizes
LKB1-dependent invasion pathways where compromised LKB1
function could promote NSCLC metastasis.
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The tumor suppressor LKB1 is mutated in 20 to 30% ofnon-small cell lung cancers (NSCLCs)1 and ranks as the
third highest mutated gene in lung adenocarcinoma after p53
and Ras.1–3 Consequently, LKB1 has moved from a relatively
understudied protein to a major player in NSCLC, especially
NSCLC metastasis. Similar to other emerging pathways, the
molecular details and biologic consequences of LKB1-depen-
dent events have not been fully elucidated. The purpose of
this review is to summarize LKB1 function and highlight
LKB1-dependent molecular pathways that when compro-
mised could contribute to lung cancer metastasis.
LKB1 AND LUNG METASTASIS
LKB1 is a serine/threonine kinase (formerly known as
STK11)4 that contains two nuclear localization sequences, a
central kinase domain, and a C-terminal farnesylation motif,5
where the N- and C-terminal noncatalytic regions share no
relatedness to other proteins. LKB1 activity is regulated by the
pseudokinase STE20-related kinase adaptor alpha and the scaf-
folding protein mouse protein 25 alpha (MO25) through a
phosphorylation-independent mechanism.6,7 The canonical tar-
get of LKB1 is the energy regulated AMP-activated protein
kinase (AMPK), although LKB1 phosphorylates other AMPK
family members such as microtubule-associated protein (MAP)/
microtubule affinity-regulating kinases (MARK) 1 to 4 and
Snf1-like kinases (NUAK) 1 and 2.8 AMPK itself is a metabolic
master regulator that is activated during reduced energy avail-
ability or hypoxic stress.9,10 Phosphorylation of the AMPK-
activation loop at Thr172 by LKB1 is essential for AMPK
catalytic activity,11,12 and AMPK function is compromised in
lkb1-/- mouse embryonic fibroblasts but can be restored after
LKB1 reconstitution.13–15
In a seminal publication, LKB1 function was assessed
using a mutant k-ras-driven mouse model of lung cancer.16 In
this model, LKB1 inactivation alone was insufficient for
pulmonary neoplasia, but LKB1 inactivation in mutant k-ras
tumors led to adeno, squamous, and large cell carcinomas of
the lung. Importantly, these mice also had more frequent
metastasis compared with tumors lacking p53 or Ink4a/Arf,
and increased tumor burden and larger lesions compared with
k-ras mutant-only mice. Although the molecular details un-
derlying these events were not clear, this data supported a
role for LKB1 inactivation in the progression and metastasis
of K-ras-initiated lung tumors. These findings, along with its
high mutation rate thrust LKB1 into the spotlight as an
important regulator of lung cancer progression and metasta-
sis. Thus, each of the following three sections summarizes
how LKB1 participates in the respective metastasis-related
pathway (Figure 1) and how a compromised LKB1 pathway
could trigger or promote NSCLC metastasis.
CELL POLARITY AND ENERGY STRESS
In most organs, epithelial cells polarize to form an
apical and basal region that provides directional transport of
molecules across the epithelial sheet. LKB1 is proposed to be
a master regulator of epithelial cell polarity, because LKB1
activation causes cell autonomous polarization, even in the
absence of junctional cell-cell contacts.17 LKB1-induced po-
larization likely occurs through AMPK, because in Drosoph-
ila, LKB1-AMPK coordinates epithelial polarity in an ener-
gy-dependent manner,18 and in mammalian cells, AMPK
regulates tight junction assembly during polarization.19,20
Because a loss of epithelial polarity may serve as a prereq-
uisite for epithelial to mesenchymal transition (EMT)21–24
and subsequent tumor invasion,23,24 compromised LKB1
could trigger aberrant polarity and EMT induction. In fact,
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LKB1 loss induces EMT in transformed human small airway
epithelial cells,25 which raises the unanswered question of
whether LKB1 mutant NSCLC patients display EMT and
whether this drives metastasis.
Cell polarization is also evident in migrating cells,
which generate directional migration by an actin-based la-
mellipodia. LKB1 is necessary for lung cancer polarization
during migration, where LKB1 rapidly translocates to the
cellular leading edge in NSCLC cell lines to associate with
actin, and regulate active cdc42 (small Rho GTPase)26
through an LKB1-active cdc42-p21-activated kinase (PAK1)
complex.27 Loss of LKB1 activity reduces PAK1 and cdc42
activity, presumably resulting in the aberrant cell polarity
observed.27 Interestingly, another study in human colon can-
cer cell lines and mouse embryonic fibroblasts shows that
LKB1 represses PAK1 by phosphorylation at a newly
described Thr109 site.28 It is not clear why LKB1 seems to
both repress and activate PAK1 function,27,28 although it
may depend on p53 status28 or whether cells are motile;
nevertheless, a dysregulation of PAK1 through defective
LKB1 signaling could lead to aberrant polarity and direc-
tional migration. Whether AMPK participates in these
events is unclear, but AMPK also regulates mammalian
cell motility and its loss causes directional migration
defects,29 suggesting a potential role for AMPK in energy-
dependent regulation of cell motility.
It should be noted that most work on the LKB1-AMPK
axis has focused on their cytosolic role, but LKB1 also
functions in the nucleus,30–32 and more recently, stress-in-
duced AMPK activity promotes transcription by histone 2B
phosphorylation.33 Among the potential AMPK-regulated
transcripts, dual specificity phosphatases (DUSPs) may be
relevant to metastasis, because the LKB1-AMPK meta-
bolic checkpoint induces DUSP1 and 2 transcription by a
p53-dependent mechanism,34 and DUSPs negatively regu-
late mitogen-activated protein kinase (MAPK) phosphor-
ylation.35 It will be interesting to determine whether
AMPK transcriptional regulation of DUSPs or other cancer
relevant proteins plays a role in lung cancer metastasis.
CELL DETACHMENT AND ADHESION
Cell detachment and adhesion are necessary for motile
cells to interact with the microenvironment and generate a
force to move.36 Primary and metastatic de novo lung cancers
from mutant k-ras/lkb1 tumors show defects in cell adhesion,
whereby src is activated, and focal adhesion is impaired.37
Specifically, focal adhesion kinase (FAK) phosphorylation is
increased in LKB1 mutant tumors, and this correlates with
increased invasion and migration. FAK is a cell-adhesion
protein that signals through integrins and in some cases
growth factor receptors to relay cues from the extracellular
matrix (ECM) through the plasma membrane and into the
cytoplasm.38 There it acts as a signaling node at adhesion
sites to promote cytoskeletal reorganization, adhesion, migra-
tion, and survival.38,39 Thus, the increased metastatic poten-
tial of mutant k-ras/lkb1 tumors could be due to stronger
adhesion to the ECM, which may increase the likelihood of
single cells to successfully escape the primary tumor and
navigate through the microenvironment.
Interestingly, Zagorska et al.40 suggested a potentially
different mechanism for LKB1-mediated adhesion by an
LKB1-NUAK1 pathway. In this case, LKB1-NUAK1 reg-
ulates cell detachment and adhesion through myosin light
chain 2 and myosin phosphatase, whereby inhibition of
LKB1-NUAK1 pathway impaired cell detachment and
increased adhesion. This discovery is equally as exciting,
and it remains to be seen whether these two LKB1-
dependent adhesion pathways are linked potentially
through a FAK-src-myosin light chain kinase pathway.41
In both cases, one can envision a scenario whereby LKB1
mutant tumor cells are abnormally adherent, thereby pro-
viding a mechanism for escaping cells to firmly attach to
the ECM during invasion.
ANOIKIS
Anoikis is a form of apoptosis that is triggered by poor
contact between the cell and the ECM. Cancer cells can
become resistant to anoikis and consequently display anchor-
age-independent growth.42,43 LKB1 participates in p53-de-
pendent anoikis through the salt-inducible kinase (SIK1), an
AMPK family member.8,44 SIK1 was required for LKB1 to
promote p53-dependent anoikis and suppress anchorage-in-
dependent growth and invasion. SIK1 loss promoted meta-
static spread and survival of cells as micrometastases in the
lungs. Loss of LKB1, p53, or SIK1 resulted in anoikis
resistance and, hence, survival, despite being unattached to
the ECM. Thus, when taken in combination with the in-
creased adhesion observed in LKB1 mutant cells,37,40 LKB1
loss could provide cells not only the ability to adhere to the
ECM during invasion but also the ability to survive when
unattached.
FIGURE 1. LKB1-dependent pathways related
to motility and metastasis. LKB1-dependent
cytoplasmic pathways that regulate epithelial
cell polarity, cell polarity during motility, cell
detachment/adhesion, and anoikis. For simplic-
ity, the pathways are not shown in full.
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CLINICAL SIGNIFICANCE
A logical next step is to determine whether LKB1
mutational status can be used as a predictive marker of
metastatic disease. To our knowledge, a large-scale clinical
study in NSCLC testing this hypothesis has not been done.
Furthermore, because LKB1 signaling negatively regulates
tumor metastasis, activators of LKB1-dependent signaling
may have clinical utility. The best characterized activator of
LKB1/AMPK signaling is metformin, an antidiabetic drug.
Several epidemiological studies show decreased cancer inci-
dence in metformin-treated patients, and preclinical data
indicated that metformin has direct antitumor effects. These
works has been reviewed extensively by others.45–47 Met-
formin, however, requires LKB1 to activate AMPK function,
thus for tumors with LKB1 inactivation, phosphatidylinositol
ether lipid analogues were recently developed that can acti-
vate AMPK in LKB1-mutant NSCLC cells.48 Therefore, these
agents in particular could be used in LKB1 mutant patients to
“rescue” LKB1 defects.
Taken together, LKB1 oversees several metastasis-
related pathways discussed in this review including cell
adhesion, polarity, and anoikis. Many of these motility path-
ways are historically linked and share common signaling
molecules such as FAK, myosin, and cdc42 (Figure 1).
Precisely, how LKB1 regulates these pathways and how these
pathways interact are likely to be topics of interest over the
next few years. Furthermore, it is unclear whether all LKB1
mutations observed in patients or cell lines result in similar
phenotypes or whether certain mutations induce pathway-
specific phenotypes. In either case, a systematic evaluation of
LKB1 mutations and their effects on NSCLC invasion and
metastasis is warranted. Ultimately, an understanding of
LKB1 function and how a compromised LKB1 pathway
impacts metastasis could reveal new opportunities for pre-
dicting and controlling NSCLC metastasis.
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